Explore more publications!
Cincinnati Wellness Review
Got News to Share?

Cincinnati Wellness Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cincinnati Wellness Review.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on October 21, 2025

Solenic Medical Announces Successful Use of Its AMF Technology Under FDA Compassionate Use Authorization
October 21, 2025

Solenic Medical Announces Successful Use of Its AMF Technology Under FDA Compassionate Use Authorization

Indeterminate GlobeNewswire
PetVivo Holdings, Inc. Addresses Veterinary Industry's GEN Z Problem With Breakthrough AI License Agreement
October 21, 2025

PetVivo Holdings, Inc. Addresses Veterinary Industry's GEN Z Problem With Breakthrough AI License Agreement

Indeterminate GlobeNewswire
MediBeacon receives regulatory approval to sell the Transdermal GFR System in China
October 21, 2025

MediBeacon receives regulatory approval to sell the Transdermal GFR System in China

Indeterminate GlobeNewswire
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and…
October 21, 2025

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and…

Indeterminate GlobeNewswire
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
October 21, 2025

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

Indeterminate GlobeNewswire
AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure
October 21, 2025

AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure

Indeterminate GlobeNewswire
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
October 21, 2025

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Indeterminate GlobeNewswire
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
October 21, 2025

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Indeterminate GlobeNewswire
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
October 21, 2025

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Indeterminate GlobeNewswire
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
October 21, 2025

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Indeterminate GlobeNewswire
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
October 21, 2025

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

Indeterminate GlobeNewswire
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
October 21, 2025

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Indeterminate GlobeNewswire
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
October 21, 2025

SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

Indeterminate GlobeNewswire
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
October 21, 2025

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Indeterminate GlobeNewswire
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
October 21, 2025

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Indeterminate GlobeNewswire
RadNet to Host Investor Day on November 11, 2025
October 21, 2025

RadNet to Host Investor Day on November 11, 2025

Indeterminate GlobeNewswire
PrestoDoctor Expands Into Michigan Ahead of New Cannabis Tax Changes
October 21, 2025

PrestoDoctor Expands Into Michigan Ahead of New Cannabis Tax Changes

Indeterminate GlobeNewswire
selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
October 21, 2025

selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease

Indeterminate GlobeNewswire
Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
October 21, 2025

Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

Indeterminate GlobeNewswire
Acies Bio doubling biomanufacturing capacity with the construction of 30 m³ bioreactor
October 21, 2025

Acies Bio doubling biomanufacturing capacity with the construction of 30 m³ bioreactor

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions